MYLAN's MAXZIDE IS "APPROVABLE" AT FDA: LEDERLE TO MARKET BRAND COMPETITION TO SMITHKLINE's No. 3-RANKED DYAZIDE; FINAL APPROVAL ANTICIPATED "IMMINENTLY"

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".